HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a $48 price target.
May 14, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tourmaline Bio's stock rating was reiterated as Buy by HC Wainwright & Co. with a price target of $48, indicating a positive outlook.
The reiteration of a Buy rating and a maintained price target of $48 by a reputable analyst firm like HC Wainwright & Co. suggests a strong confidence in Tourmaline Bio's future performance. This endorsement is likely to instill positive sentiment among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100